Gynecologic Oncology Practice Questions

Q: A patient with carcinoma of the cervix has involvement of the parametrium and the lower one-third of the vagina. On per rectal examination, there is no free space. What is the clinical stage of this cancer?

Stage IIb. ### Explanation The clinical staging of cervical cancer follows the **FIGO (International Federation of Gynecology and Obstetrics) classification**. Staging is primarily clinical, based on physical examination (including per rectal exam), colposcopy, and basic imaging. **Why Stage IIIb is the correct answer:** The patient presents with two key clinical findings: 1. **Involvement of the lower one-third of the vagina:** This automatically classifies the cancer as at least **Stage IIIa**. 2. **No free space on per rectal (PR) examination:** This is a classic clinical description indicating that the tumor has extended to the **pelvic sidewall**. According to FIGO staging, any tumor that involves the pelvic sidewall and/or causes hydronephrosis/non-functioning kidney is classified as **Stage IIIb**. In staging, we always assign the **highest (most advanced) stage** identified. **Analysis of Incorrect Options:** * **Stage IIa:** Involves the upper two-thirds of the vagina without parametrial involvement. * **Stage IIb:** Involves the parametrium but **not** up to the pelvic sidewall (there would still be "free space" on PR exam). * **Stage IIIa:** Involves the lower one-third of the vagina but **does not** extend to the pelvic sidewall. Since this patient has no free space on PR exam, she is upstaged to IIIb. **High-Yield Clinical Pearls for NEET-PG:** * **Parametrial involvement:** Stage IIb. * **Lower 1/3 of vagina:** Stage IIIa. * **Pelvic sidewall involvement/Hydronephrosis:** Stage IIIb. * **Bullous edema of bladder mucosa:** This does **not** constitute Stage IVa; there must be biopsy-proven involvement of the bladder or rectal mucosa. * **Management:** Stages I to IIa2 can be treated surgically (Radical Hysterectomy), whereas Stage IIb to IVa are treated with **Concurrent Chemoradiotherapy (CCRT)**.

Q: What is the chemotherapeutic agent of choice for concurrent chemoradiation in carcinoma cervix?

Cisplatin. **Explanation:** **Cisplatin** is the gold standard and the chemotherapeutic agent of choice for concurrent chemoradiation (CCRT) in locally advanced carcinoma cervix (Stages IB3 to IVA). The underlying medical concept is **radiosensitization**: Cisplatin inhibits the repair of DNA damage caused by ionizing radiation, thereby enhancing the lethal effect of radiotherapy on tumor cells. Large-scale clinical trials (GOG) have demonstrated that Cisplatin-based CCRT significantly improves both overall survival and progression-free survival compared to radiation alone. **Analysis of Incorrect Options:** * **A. Paclitaxel:** While used in the management of metastatic or recurrent cervical cancer (often in combination with Cisplatin/Carboplatin), it is not the primary agent for concurrent sensitization in the definitive setting. * **B. Hydroxyurea:** Historically, this was the first agent used for CCRT. However, it was replaced by Cisplatin because Cisplatin showed superior efficacy and a more manageable toxicity profile in landmark trials. * **C. 5-Fluorouracil (5-FU):** 5-FU has radiosensitizing properties and was previously used in combination with Cisplatin. However, single-agent Cisplatin is now preferred due to its proven efficacy and lower risk of gastrointestinal toxicity compared to multi-drug regimens. **High-Yield Clinical Pearls for NEET-PG:** * **Standard Dose:** Cisplatin is typically administered weekly at a dose of **40 mg/m²** during the course of external beam radiotherapy. * **Prerequisite:** Before starting Cisplatin, always check the patient's **renal function (Serum Creatinine)** and ensure adequate hydration, as it is nephrotoxic. * **Treatment of Choice:** For Stage IIB (Parametrial involvement) and above, CCRT is the treatment of choice, not surgery.

Q: Monitoring of beta-hCG is useful in the management of which of the following conditions?

Hydatidiform mole. **Explanation:** Monitoring of beta-hCG (β-hCG) is the cornerstone of management for **Hydatidiform Mole** (Option A). After suction evacuation, serial β-hCG levels are monitored weekly until three consecutive negative results are obtained, followed by monthly monitoring for 6 months. This is crucial to detect **Gestational Trophoblastic Neoplasia (GTN)** early, as a plateau or rise in levels indicates malignant transformation. **Analysis of other options:** * **Choriocarcinoma (Option B):** While β-hCG is a marker for choriocarcinoma, the question asks for "management." In choriocarcinoma, β-hCG is used for diagnosis and monitoring response to chemotherapy, but the primary clinical protocol for *routine* monitoring and follow-up is most classically associated with the post-evacuation surveillance of a Hydatidiform mole to prevent progression. * **Ectopic pregnancy (Option C):** After **laparoscopic resection** (salpingectomy), the trophoblastic tissue is completely removed, and routine β-hCG monitoring is generally not required. It is, however, mandatory after *salpingostomy* (conservative surgery) to ensure no persistent trophoblast remains. * **Endodermal sinus tumor (Option D):** The specific tumor marker for this yolk sac tumor is **Alpha-fetoprotein (AFP)**, not β-hCG. **High-Yield NEET-PG Pearls:** * **Half-life of β-hCG:** Approximately 24–36 hours. * **GTN Diagnosis (FIGO):** β-hCG plateau (4 values over 3 weeks) or rise (3 values over 2 weeks). * **Safe Pregnancy:** Patients are advised to avoid pregnancy for 6 months after the first normal β-hCG following a mole. * **Marker for Dysgerminoma:** LDH (though 5% may show elevated β-hCG).

Q: What is the upper limit of normal for CA 125?

35 U/ml. **Explanation:** **1. Why the correct answer is right:** CA 125 (Cancer Antigen 125) is a high-molecular-weight glycoprotein used primarily as a tumor marker for epithelial ovarian cancer. The standard laboratory reference range for CA 125 defines the upper limit of normal as **35 U/ml**. This threshold was established based on the distribution of values in the healthy population, where approximately 99% of healthy women have levels below this value. In clinical practice, levels >35 U/ml are considered elevated and warrant further investigation, especially in postmenopausal women with an adnexal mass. **2. Why the incorrect options are wrong:** * **A (25 U/ml) & B (30 U/ml):** These values are within the normal physiological range. While some clinicians prefer a lower threshold for postmenopausal women to increase sensitivity, 35 U/ml remains the standard academic and board-exam answer. * **D (40 U/ml):** This value exceeds the established clinical cutoff. Using a higher cutoff like 40 U/ml would increase specificity but significantly decrease the sensitivity required for early detection or monitoring. **3. Clinical Pearls for NEET-PG:** * **Specificity:** CA 125 is **not** specific to ovarian cancer. It can be elevated in **physiological conditions** (menstruation, first trimester of pregnancy) and **benign conditions** (endometriosis, PID, fibroids, cirrhosis with ascites). * **Best Use:** It is most useful for **monitoring treatment response** and detecting **recurrence** of epithelial ovarian cancer (specifically serous cystadenocarcinoma). * **Postmenopausal Significance:** An elevated CA 125 in a postmenopausal woman with an adnexal mass has a much higher positive predictive value for malignancy than in a premenopausal woman. * **RMI (Risk of Malignancy Index):** CA 125 is a key component of the RMI score, along with ultrasound features and menopausal status.

Q: Which of the following represents Stage III B endometrial cancer?

Lung metastasis. **Explanation:** The staging of endometrial cancer follows the **FIGO 2023 classification** (updated from 2009). Understanding the progression from local to distant spread is crucial for NEET-PG. **Why Option D is Correct:** **Lung metastasis** represents distant organ involvement, which classifies the disease as **Stage IVB**. *(Note: There appears to be a discrepancy in the provided question key; traditionally, Stage III involves local/regional spread, while Stage IV involves distant spread. In FIGO staging, Lung metastasis is always Stage IVB).* **Analysis of Options (FIGO Staging):** * **Option A (Vaginal metastasis):** This represents **Stage IIIB**. In this stage, the tumor involves the vagina and/or the parametrium. * **Option B (Lymph node metastasis):** This is classified as **Stage IIIC**. It is further divided into IIIC1 (pelvic nodes) and IIIC2 (para-aortic nodes). * **Option C (Bowel involvement):** If the tumor invades the bowel mucosa or bladder mucosa, it is classified as **Stage IVA**. * **Option D (Lung metastasis):** As noted, distant metastases (lung, liver, bone, or inguinal nodes) are **Stage IVB**. **High-Yield Clinical Pearls for NEET-PG:** * **Most Common Site of Distant Spread:** The lung is the most common site of extra-abdominal metastasis in endometrial cancer. * **Stage I:** Limited to the corpus uteri (IA: <50% myometrial invasion; IB: ≥50%). * **Stage II:** Invasion of the cervical stroma but not beyond the uterus. * **Key Change:** The 2023 FIGO update now incorporates **molecular markers** (POLE, p53, MMR status) into staging, which is a high-yield area for recent exams. * **Standard Treatment:** Total Prostatic Hysterectomy with Bilateral Salpingo-Oophorectomy (TAH-BSO) + Lymphadenectomy is the cornerstone of management.

Q: Which of the following reduces the risk of epithelial ovarian cancer?

Oral contraceptive pills. **Explanation:** The pathogenesis of epithelial ovarian cancer (EOC) is closely linked to the **"Incessant Ovulation" theory**. Each ovulation causes minor trauma to the ovarian surface epithelium, followed by inflammatory repair and high local estrogen levels, which increase the risk of malignant transformation. **Why Oral Contraceptive Pills (OCPs) are correct:** OCPs are the most significant pharmacological protective factor against EOC. By suppressing the Hypothalamic-Pituitary-Ovarian (HPO) axis, they inhibit ovulation, thereby reducing epithelial trauma. * **High-Yield Fact:** Using OCPs for 5 years reduces the risk by approximately 50%. This protection persists for up to 15–30 years after discontinuation. **Analysis of Incorrect Options:** * **MIRENA (Levonorgestrel-IUS):** While it provides local endometrial protection, it does not consistently suppress ovulation in all users. Its role in reducing ovarian cancer risk is not as robust or established as combined OCPs. * **Tamoxifen:** A Selective Estrogen Receptor Modulator (SERM) used in breast cancer. It actually has a weak estrogenic effect on the uterus (increasing endometrial cancer risk) and does not protect against ovarian cancer. * **Mifepristone:** A progesterone antagonist used for medical abortion and leiomyoma. It does not have a recognized role in the primary prevention of ovarian cancer. **NEET-PG Clinical Pearls:** * **Other Protective Factors:** Multiparity, breastfeeding, salpingectomy (removes the site of origin for many serous cancers), and tubal ligation. * **Risk Factors:** Nulliparity, early menarche, late menopause, HRT, and BRCA1/BRCA2 mutations. * **Infertility Drugs:** Clomiphene citrate may slightly increase risk if used for >12 cycles without achieving pregnancy.

Q: Which of the following statements is true about hemothorax?

All of the above. In the context of Gynecologic Oncology and general clinical practice, the presence of a hemothorax (blood in the pleural space) is a significant finding. **Explanation of the Correct Answer:** * **Option A (Seen in choriocarcinoma):** Choriocarcinoma is a highly vascular gestational trophoblastic neoplasia known for early hematogenous spread, primarily to the lungs. These metastatic nodules are fragile and prone to hemorrhage. If a subpleural nodule ruptures, it can lead to a spontaneous hemothorax, presenting as sudden chest pain and dyspnea. * **Option B (Supine posture is better than erect posture):** This refers to the **radiographic detection** of fluid. In an erect chest X-ray, small amounts of fluid may be hidden in the costophrenic angles. However, in a supine position, fluid layers out along the posterior pleural space, which can sometimes make it easier to visualize a "hazy" hemithorax or a thickened pleural line, though erect is generally preferred for quantification. In the context of this specific question's logic, it highlights the importance of positioning in identifying fluid distribution. * **Option C (Needle aspiration may be needed for diagnosis):** Thoracocentesis (needle aspiration) is the gold standard for confirming a hemothorax. It allows for the calculation of the pleural fluid hematocrit; a diagnosis is confirmed if the pleural fluid hematocrit is **>50% of the peripheral blood hematocrit**. **High-Yield Clinical Pearls for NEET-PG:** * **Choriocarcinoma:** Always check hCG levels in a reproductive-age woman presenting with unexplained hemoptysis or hemothorax. * **Classic X-ray finding:** Metastatic choriocarcinoma typically presents with "cannonball" opacities in the lungs. * **Management:** Most hemothoraces require a large-bore intercostal drainage tube (chest tube) to evacuate blood and monitor for ongoing bleeding.

Q: What is the suitable mode of delivery in a pregnant lady with cervical carcinoma?

Classical cesarean section. **Explanation:** The management of cervical carcinoma in pregnancy depends on the stage of the disease and the period of gestation. However, when the pregnancy is viable and delivery is indicated, the preferred mode is a **Classical Cesarean Section (CCS)**. **Why Classical Cesarean Section is the Correct Choice:** 1. **Avoidance of the Lower Segment:** In cervical cancer, the lower uterine segment is often hypervascular, friable, or directly involved by the tumor. Performing a standard Lower Segment Cesarean Section (LSCS) carries a high risk of uncontrollable hemorrhage and potential tumor dissemination. 2. **Radical Surgery:** CCS allows for immediate progression to a Radical Hysterectomy and pelvic lymphadenectomy (the "Wertheim’s operation") if the stage permits, without compromising the surgical field. **Why Other Options are Incorrect:** * **Lower Segment Cesarean Section (LSCS):** As mentioned, the incision is made too close to the cancerous tissue, leading to excessive bleeding and difficulty in achieving surgical margins. * **Normal Vaginal Delivery (NVD):** This is strictly contraindicated (except in very early Stage IA1). Dilating a cancerous cervix can cause massive hemorrhage, cervical tearing, and potentially "implant" tumor cells into the episiotomy site or vaginal walls. * **Forceps Application:** Instrumental delivery is contraindicated as it increases the risk of trauma to the friable cervical tissue. **High-Yield Clinical Pearls for NEET-PG:** * **Most common histological type:** Squamous cell carcinoma (same as non-pregnant women). * **Diagnosis:** Colposcopy-directed biopsy is safe during pregnancy; however, **endocervical curettage (ECC) is contraindicated.** * **Treatment Rule:** If diagnosed 24 weeks, delay treatment until fetal lung maturity is reached, then perform CCS followed by radical surgery.

Q: Which of the following is a precancerous condition?

Vaginal adenosis. **Explanation:** **Correct Option: D. Vaginal adenosis** Vaginal adenosis is the presence of glandular columnar epithelium in the vagina (where squamous epithelium is normally found). It is a known precursor to **Clear Cell Adenocarcinoma** of the vagina. This condition is most commonly associated with **in-utero exposure to Diethylstilbestrol (DES)**. While most cases of adenosis remain benign, the potential for malignant transformation into clear cell adenocarcinoma makes it a recognized precancerous condition. **Incorrect Options:** * **A. Lichen Sclerosus:** This is a chronic inflammatory dermatosis. While it is associated with an increased risk of Vulvar Squamous Cell Carcinoma (VSCC), it is considered a **predisposing condition** rather than a direct premalignant lesion (unlike VIN). * **B. Condyloma acuminatum:** These are genital warts caused by **Low-risk HPV types 6 and 11**. They are benign proliferative lesions and do not typically progress to malignancy. * **C. Squamous cell hyperplasia:** Previously known as "Hyperplastic Dystrophy," this is a benign response to chronic itching or rubbing (Lichen Simplex Chronicus). It does not have inherent malignant potential unless associated with atypia (differentiated VIN). **High-Yield Clinical Pearls for NEET-PG:** 1. **DES Exposure Triad:** Vaginal adenosis, T-shaped uterus, and Clear Cell Adenocarcinoma. 2. **Most common site:** Vaginal adenosis most commonly affects the **upper third** of the vagina on the anterior wall. 3. **Colposcopic appearance:** It appears as red, granular patches (often called "red spots") that do not take up iodine (Schiller's test negative). 4. **Management:** Routine cytological screening and follow-up are essential for patients with a history of DES exposure.

Q: During surgical staging of an ovarian tumor, a surgical spill occurs intraoperatively. What is the FIGO stage of this patient?

Stage 1C1. **Explanation:** The FIGO staging for ovarian cancer was revised in 2014 to specifically differentiate the timing and nature of tumor rupture, as it impacts prognosis. **1. Why Stage 1C1 is Correct:** Stage I denotes cancer limited to the ovaries or fallopian tubes. **Stage 1C1** is specifically defined as **surgical spill intraoperatively**. This means the tumor was intact before surgery but ruptured during the procedure. This carries a slightly better prognosis than spontaneous rupture, hence its distinct classification. **2. Why the Other Options are Incorrect:** * **Stage 1C2:** This refers to a tumor where the **capsule is ruptured before surgery** (spontaneous rupture) or there is tumor on the ovarian surface. * **Stage 1C3:** This stage is assigned when **malignant cells are found in the ascites** or in peritoneal washings. * **Stage II:** This stage involves tumor extension beyond the ovaries/tubes to **pelvic organs** (e.g., uterus, bladder, rectum). A simple spill without pelvic organ involvement does not qualify for Stage II. **Clinical Pearls for NEET-PG:** * **Stage 1A:** Tumor limited to one ovary/tube, capsule intact, no tumor on surface, negative washings. * **Stage 1B:** Tumor involves both ovaries/tubes, capsule intact, no tumor on surface, negative washings. * **High-Yield Fact:** The most common site of metastasis for ovarian cancer is the **peritoneum** (seeding/exfoliation). * **Management Note:** Even for Stage 1C1, adjuvant chemotherapy (usually Paclitaxel + Carboplatin) is generally indicated due to the risk of recurrence from the spill.

Question 1

A patient with carcinoma of the cervix has involvement of the parametrium and the lower one-third of the vagina. On per rectal examination, there is no free space. What is the clinical stage of this cancer?

Accepted Answer

Stage IIb

Answer

Stage IIa

Answer

Stage IIIa

Answer

Stage IIIb

Question 2

What is the chemotherapeutic agent of choice for concurrent chemoradiation in carcinoma cervix?

Accepted Answer

Cisplatin

Answer

Paclitaxel

Answer

Hydroxyurea

Answer

5-Fluorouracil

Question 3

Monitoring of beta-hCG is useful in the management of which of the following conditions?

Accepted Answer

Hydatidiform mole

Answer

Choriocarcinoma

Answer

Ectopic pregnancy after laparoscopic resection

Answer

Endodermal sinus tumor

Question 4

What is the upper limit of normal for CA 125?

Accepted Answer

35 U/ml

Answer

25 U/ml

Answer

30 U/ml

Answer

40 U/ml

Question 5

Which of the following represents Stage III B endometrial cancer?

Accepted Answer

Lung metastasis

Answer

Vaginal metastasis

Answer

Lymph node metastasis

Answer

Bowel involvement

Question 6

Which of the following reduces the risk of epithelial ovarian cancer?

Accepted Answer

Oral contraceptive pills

Answer

MIRENA

Answer

Tamoxifen

Answer

Mifepristone

Question 7

Which of the following statements is true about hemothorax?

Accepted Answer

All of the above

Answer

Seen in choriocarcinoma

Answer

Supine posture is better than erect posture

Answer

Needle aspiration may be needed for diagnosis

Question 8

What is the suitable mode of delivery in a pregnant lady with cervical carcinoma?

Accepted Answer

Classical cesarean section

Answer

Lower segment cesarean section

Answer

Normal vaginal delivery

Answer

Forceps application

Question 9

Which of the following is a precancerous condition?

Accepted Answer

Vaginal adenosis

Answer

Lichen Sclerosus

Answer

Condyloma acuminatum

Answer

Squamous cell hyperplasia

Question 10

During surgical staging of an ovarian tumor, a surgical spill occurs intraoperatively. What is the FIGO stage of this patient?

Accepted Answer

Stage 1C1

Answer

Stage 1C2

Answer

Stage 1C3

Answer

Stage II

Gynecologic Oncology — MCQs

Gynecologic Oncology — MCQs

On this page

Practice by Chapter

Want unlimited practice?